View Author
patient plasma topotecan cancer lactone study concentration sample pharmacokinetic cisplatin phase 9- ac administration analysis level blood carboxylate tumor paclitaxel infusion treatment cpt -11 course sn -38 table urine toxicity ratio verweij 9- ac lactone -11 schedule -38 lurtotecan oncol combination assay value compound camptothecin activity method irinotecan sparreboom verweij j agent platinum grade effect result inhibitor clearance topotecan lactone exposure range lactone form topoisomerase model sunitinib plasma samples dose level 1998. variability determination curve solution volume sequence phase i phase i study ifosfamide antitumor activity 5 days disposition dosing stoter g hslc 22a carboplatin carboxylate form blood samples
10 Most Recent Publications
|
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
(Article)
Hamberg, P. Steeghs, N. Loos, W.J. Biessen, D. van de Hollander, M. den Tascilar, M. Verweij, J. Gelderblom, A.J. Sleijfer, S. |
2010-06-08
|
|
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)
(Article)
Burger, H. Zoumaro-Djayoon, A. Boersma, A.W.M. Helleman, J. Berns, P.M.J.J. Mathijssen, R.H.J. Loos, W.J. Wiemer, E.A.C. |
2010-02-01
|
|
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study
(Article)
Konings, I.R.H.M. Sleijfer, S. Matthijsen, R.H.J. Bruijn, P. de Ghobadi Moghaddam-Helmantel, I.M. Dam, L.M. van Wiemer, E.A.C. Verweij, J. Loos, W.J. |
2010-01-01
|
|
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry
(Article)
Bruijn, P. de Moghaddam-Helmantel, I.M.G. Jonge, M.J.A. de Meyer, T. Lam, M.H. Verweij, J. Wiemer, E.A.C. Loos, W.J. |
2009-12-05
|
|
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study
(Article)
Mom, C.H. Verweij, J. Oldenhuis, C.N.A.M. Gietema, J.A. Fox, N.L. Miceli, R. Eskens, F.A.L.M. Loos, W.J. Vries, E.G.E. de Sleijfer, S. |
2009-09-01
|
|
Continuous ambulatory peritoneal dialysis: Pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment
(Article)
Heijns, J.B. Burg, M.E.L. van der Gelder, T. van Fieren, M.W.J.A. Bruijn, P. de Gaast, A. van der Loos, W.J. |
2008-10-01
|
|
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan
(Article)
Loos, W.J. Verweij, J. Kehrer, D.F.S. Bruijn, P. de Groot, F.M.H. de Hamilton, M. Nooter, K. Stoter, G. Sparreboom, A. |
2002-01-01
|
|
Effects of St. John's wort on irinotecan metabolism
(Article)
Mathijssen, R.H.J. Verweij, J. Bruijn, P. de Loos, W.J. Sparreboom, A. |
2002-01-01
|
|
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
(Article)
Mathijssen, R.H.J. Alphen, R.J. van Verweij, J. Loos, W.J. Nooter, K. Stoter, G. Sparreboom, A. |
2001-01-01
|
|
Pharmaceutical and Biomedical Aspects of Topoisomerase I Inhibitors
(Doctoral Thesis)
Loos, W.J. |
2000-11-15
|
